ArticleJournal of veterinary internal medicine2026
Evaluation of a canine hemoglobin A1c point-of-care assay: analytical validation, clinical utility, and establishing a population-based reference interval.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHemoglobin A1c (HbA1c) assay validation is essential for establishing analytical reliability, evaluating discrimination between diabetic and non-diabetic (NDM) dogs, and establishing reference intervals. HYPOTHESIS/
objectivesValidate a canine HbA1c point-of-care analyzer (Vet Chroma™), evaluate its diagnostic performance, and establish a reference interval in healthy dogs. ANIMALS: Fifty-one diabetic, 44 NDM controls, and 42 healthy client-owned dogs.
methodsProspective validation of precision, linearity, interference, and storage stability. Method comparison used an immunoturbidimetric comparator assay (Olympus DxC 700 AU). Diagnostic performance was evaluated via receiver operating characteristic (ROC) analysis, likelihood ratios, and odds ratios.
resultsAverage intra- and inter-assay coefficients of variation were 3.92% and 8.47%. Linearity over the clinical range (0.86%-6.27% HbA1c%) was strong (R2 = 0.973) with minor constant bias. HbA1c remained stable for 5 days at 4 °C and up to 3 months at both -20 and -80 °C, but not reliably at 6 months. Lipemia and icterus exhibited variable interfering effects. Method comparison indicated non-interchangeability with the comparator assay. Diabetic dogs had significantly higher HbA1c than NDM (mean 5.10% vs 1.58%). ROC analysis yielded an AUC of 0.969, with a cutoff > 3.22% achieving 90.20% sensitivity and 100% specificity. The positive likelihood ratio was not estimable, and the odds ratio was 22.90 (95% CI, 3.60-146.90). Healthy young dogs' reference interval was 1.25% (90% CI, 1.19-1.59) to 2.75% (90% CI, 2.56-2.90). CONCLUSIONS AND CLINICAL IMPORTANCE: The Vet Chroma™ provides reliable HbA1c measurements in canine whole blood and effectively discriminates diabetic from non-diabetic dogs. Results should be interpreted alongside clinical and clinicopathologic findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.